Alaunos Therapeutics Inc TCRT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
-
Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
-
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 2.93M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,350.66
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 1
- Website
- https://www.alaunos.com
Valuation
|
Metric
|
TCRT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 11.55 |
Price/Sales | 2,350.66 |
Price/Cash Flow | — |
Price/Earnings
TCRT
Financial Strength
|
Metric
|
TCRT
|
|---|---|
Quick Ratio | 0.14 |
Current Ratio | 0.77 |
Interest Coverage | — |
Quick Ratio
TCRT
Profitability
|
Metric
|
TCRT
|
|---|---|
Return on Assets (Normalized) | −116.70% |
Return on Equity (Normalized) | −163.87% |
Return on Invested Capital (Normalized) | −163.87% |
Return on Assets
TCRT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!#!P$$ | LOCK|%?#$D | $129B | |||
| Moderna Inc
MRNA
| LOCK|$&sRRtT | LOCK|!# | $94B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|m?Kt#>G | LOCK|$s$%t | $82B | |||
| argenx SE ADR
ARGX
| LOCK|>$ZGjM | LOCK|!Bx | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^q@z>Xt | LOCK|W$ | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|mNxtbX | LOCK|rL$x | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|j?#Hs^P | LOCK|nnc!N | $27B | |||
| Incyte Corp
INCY
| LOCK|Wy>kC$ | LOCK|NW | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|v##NWJj | LOCK|$kK | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|tNy&$Q | LOCK|@^ | $14B |
United States